Recent Updates
Recently added Catalysts
CODX Positive Sentiment Score: 65/100

Co-Diagnostics, Inc. to Participate in Gilmartin Group Annual Emerging Growth Showcase on Sept 21

Thursday, September 21, 2023 1 min read
Key Takeaway: Co-Diagnostics, Inc. will participate in the Gilmartin Group Annual Emerging Growth Showcase on September 21, 2023. CEO Dwight Egan is set to discuss the progress of the forthcoming Co-Dx PCR Home platform during a fireside chat. The platform is currently under FDA review and is not available for consumer purchase at this time. This event highlights the company's advancements in molecular diagnostics technology.

Market Sentiment Analysis

POSITIVE FACTORS

  • Co-Diagnostics will present its advancements at a noteworthy event.
  • The CEO will discuss the progress of the Co-Dx PCR Home platform.
  • The company's unique patented technologies are at the forefront of diagnostics.

CONCERNS & RISKS

  • The Co-Dx PCR Home platform is still subject to FDA review.
  • The platform is not currently available for sale.

Full Press Release Details

SALT LAKE CITY, Sept. 21, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the Gilmartin Group Annual Emerging Growth Showcase.
Dwight Egan, Company CEO, will be participating in a fireside chat discussing Company progress on its forthcoming Co-Dx PCR Home™ platform on Thursday, September 21 at 11:00 AM ET. The discussion can be accessed virtually through the Events and Webcasts section of the Co-Diagnostics website.
The Co-Dx PCR Home platform is subject to FDA review and is not available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR Home™ platform and to locate genetic markers for use in applications other than infectious disease.
SOURCE Co-Diagnostics

21 %

more press release views with

Frequently Asked Questions

What is Co-Diagnostics, Inc. known for?

Co-Diagnostics, Inc. specializes in developing molecular diagnostic tests.

Who will represent Co-Diagnostics at the showcase?

CEO Dwight Egan will represent Co-Diagnostics at the Gilmartin Group showcase.

When is the presentation at the showcase?

The presentation is on September 21 at 11:00 AM ET.

Is the Co-Dx PCR Home platform available for purchase?

No, the Co-Dx PCR Home platform is under FDA review and not for sale.

What type of tests does Co-Diagnostics develop?

Co-Diagnostics develops tests based on nucleic acid detection and analysis.

Tags: CODX Viatris Investor Conferences Healthcare Co-Diagnostics molecular diagnostics Gilmartin Group FDA review Co-Dx PCR Home
Last updated: Sep 21, 2023